- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | AccuStem Sciences, Inc.: AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) | 257 | GlobeNewswire (Europe) | Initial study will enable further collaboration on the predictive capabilities of StemPrintERPHOENIX, Jan. 08, 2026), a clinical stage diagnostics company dedicated to improving outcomes for patients... ► Artikel lesen | |
| 26.11.25 | Accustem Sciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11.25 | Accustem Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.09.25 | AccuStem Sciences, Inc.: AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning | 393 | GlobeNewswire (Europe) | PHOENIX, Ariz. and LONDON, Sept. 17, 2025), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based... ► Artikel lesen | |
| 16.09.25 | AccuStem Sciences, Inc.: AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th | 271 | GlobeNewswire (Europe) | Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comPHOENIX and LONDON, Sept. 16, 2025), a clinical stage diagnostics... ► Artikel lesen | |
| ACCUSTEM SCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.08.25 | Accustem Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.06.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 253 | GlobeNewswire (Europe) | LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 13.06.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 265 | GlobeNewswire (Europe) | LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman... ► Artikel lesen | |
| 28.04.25 | AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening | 412 | GlobeNewswire (Europe) | LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk... ► Artikel lesen | |
| 21.04.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 273 | GlobeNewswire (Europe) | LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 16.04.25 | AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan | 350 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer... ► Artikel lesen | |
| 10.04.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 306 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 04.04.25 | AccuStem Sciences, Inc.: AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States | 428 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer... ► Artikel lesen | |
| 18.03.25 | AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test | 361 | GlobeNewswire (Europe) | AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026
LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 662,80 | -0,27 % | REGENERON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| GENMAB | 263,50 | +0,84 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025 | Company Announcement Net sales of DARZALEX- in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 |
ACCUSTEM SCIENCES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACCUSTEM SCIENCES INC finden Sie auf Wallstreet Online.